MaryAnn B Wilbur1, Diana B Mannschreck2, Ana M Angarita1, Rayna K Matsuno3, Edward J Tanner1, Rebecca L Stone1, Kimberly L Levinson1, Sarah M Temkin1, Martin A Makary4, Curtis A Leung5, Amy Deutschendorf5, Peter J Pronovost4, Amy Brown1, Amanda N Fader6. 1. Kelly Gynecologic Oncology Service, Johns Hopkins Hospital, Baltimore, MD, United States. 2. Johns Hopkins School of Medicine, Baltimore, MD, United States. 3. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, United States. 4. Division of Health Policy & Management, Johns Hopkins School of Public Health, Baltimore, MD, United States. 5. Care Coordination and Clinical Resource Management, Johns Hopkins Hospital, Baltimore, MD, United States. 6. Kelly Gynecologic Oncology Service, Johns Hopkins Hospital, Baltimore, MD, United States. Electronic address: afader1@jhmi.edu.
Abstract
OBJECTIVES: Thirty-day readmission is used as a quality measure for patient care and Medicare-based hospital reimbursement. The primary study objective was to describe the 30-day readmission rate to an academic gynecologic oncology service. Secondary objectives were to identify risk factors and costs related to readmission. METHODS: This was a retrospective, concurrent cohort study of all surgical admissions to an academic, high volume gynecologic oncology service during a two-year period (2013-2014). Data were collected on patient demographics, medical comorbidities, psychosocial risk factors, and results from a hospital discharge screening survey. Mixed logistic regression was used to identify factors associated with 30-day readmission and costs of readmission were assessed. RESULTS: During the two-year study period, 1605 women underwent an index surgical admission. Among this population, a total of 177 readmissions (11.0%) in 135 unique patients occurred. In a surgical subpopulation with >1 night stay, a readmission rate of 20.9% was observed. The mean interval to readmission was 11.8days (SD 10.7) and mean length of readmission stay was 5.1days (SD 5.0). Factors associated with readmission included radical surgery for ovarian cancer (OR 2.87) or cervical cancer (OR 4.33), creation of an ostomy (OR 11.44), a Charlson score of ≥5 (OR 2.15), a language barrier (OR 3.36), a median household income in the lowest quartile (OR 6.49), and a positive discharge screen (OR 2.85). The mean cost per readmission was $25,416 (SD $26,736), with the highest costs associated with gastrointestinal complications at $32,432 (SD $32,148). The total readmission-related costs during the study period were $4,523,959. CONCLUSIONS: Readmissions to a high volume gynecologic oncology service were costly and related to radical surgery for ovarian and cervical cancer as well as to medical, socioeconomic and psychosocial patient variables. These data may inform interventional studies aimed at decreasing unplanned readmissions in gynecologic oncology surgical populations.
OBJECTIVES: Thirty-day readmission is used as a quality measure for patient care and Medicare-based hospital reimbursement. The primary study objective was to describe the 30-day readmission rate to an academic gynecologic oncology service. Secondary objectives were to identify risk factors and costs related to readmission. METHODS: This was a retrospective, concurrent cohort study of all surgical admissions to an academic, high volume gynecologic oncology service during a two-year period (2013-2014). Data were collected on patient demographics, medical comorbidities, psychosocial risk factors, and results from a hospital discharge screening survey. Mixed logistic regression was used to identify factors associated with 30-day readmission and costs of readmission were assessed. RESULTS: During the two-year study period, 1605 women underwent an index surgical admission. Among this population, a total of 177 readmissions (11.0%) in 135 unique patients occurred. In a surgical subpopulation with >1 night stay, a readmission rate of 20.9% was observed. The mean interval to readmission was 11.8days (SD 10.7) and mean length of readmission stay was 5.1days (SD 5.0). Factors associated with readmission included radical surgery for ovarian cancer (OR 2.87) or cervical cancer (OR 4.33), creation of an ostomy (OR 11.44), a Charlson score of ≥5 (OR 2.15), a language barrier (OR 3.36), a median household income in the lowest quartile (OR 6.49), and a positive discharge screen (OR 2.85). The mean cost per readmission was $25,416 (SD $26,736), with the highest costs associated with gastrointestinal complications at $32,432 (SD $32,148). The total readmission-related costs during the study period were $4,523,959. CONCLUSIONS: Readmissions to a high volume gynecologic oncology service were costly and related to radical surgery for ovarian and cervical cancer as well as to medical, socioeconomic and psychosocialpatient variables. These data may inform interventional studies aimed at decreasing unplanned readmissions in gynecologic oncology surgical populations.
Authors: Daniel R Evans; Alexander L Lazarides; Mark M Cullen; Julia D Visgauss; Jason A Somarelli; Dan G Blazer; Brian E Brigman; William C Eward Journal: Ann Surg Oncol Date: 2021-05-20 Impact factor: 5.344
Authors: Anna L Romanova; Charelle Carter-Brooks; Kristine M Ruppert; Halina M Zyczynski Journal: Am J Obstet Gynecol Date: 2019-11-13 Impact factor: 8.661
Authors: Peter S Kirk; Ted A Skolarus; Bruce L Jacobs; Yongmei Qin; Benjamin Li; Michael Sessine; Xiang Liu; Kevin Zhu; Scott M Gilbert; Brent K Hollenbeck; Ken Urish; Jonathan Helm; Mariel S Lavieri; Tudor Borza Journal: BJU Int Date: 2019-08-11 Impact factor: 5.588
Authors: Allison Squires; Chenjuan Ma; Sarah Miner; Penny Feldman; Elizabeth A Jacobs; Simon A Jones Journal: Int J Nurs Stud Date: 2021-10-01 Impact factor: 6.612
Authors: Martijn Boon; Chris Martini; H Keri Yang; Shuvayu S Sen; Rob Bevers; Michiel Warlé; Leon Aarts; Marieke Niesters; Albert Dahan Journal: PLoS One Date: 2018-05-23 Impact factor: 3.240